Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

356 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-24

Study Completion Date

2024-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, single-arm retrospective registry (chart review) is being conducted to confirm the clinical performance and safety of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft throughout the device functional lifetime for each indication area.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

NCT00617279

Peripheral Arterial Occlusive Disease

TERMINATED PHASE4

Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

NCT04907240

Peripheral Artery Disease Popliteal Aneurysm Hemodialysis Access +2 more

RECRUITING

GORE-TEX PROPATEN Vascular Graft Study

NCT00205790

Peripheral Vascular Diseases

COMPLETED NA

GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis

NCT00737672

Renal Failure Hemodialysis

COMPLETED PHASE3

Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)

NCT02462876

Popliteal Artery Aneurysm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Up to 9 sites in Europe will be required to enroll 353 patients that have had treatment with GORE-TEX® Vascular Grafts or GORE® PROPATEN® Vascular Grafts in the following indication areas:

144 patients in PAD Cohort

* 72 Patients with any GORE-TEX® Vascular Graft
* 72 Patients with GORE® PROPATEN® 65 patients in Aortic Aneurysm Cohort with GORE-TEX® Vascular Graft 144 patients in Dialysis Access Cohort
* 72 patients implanted with any GORE-TEX® Vascular Graft
* 72 Patients implanted with Patients with GORE® PROPATEN®

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PAD - Peripheral Arterial Disease AAA - Abdominal Aortic Aneurysm End-Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PAD Cohort

Patient was treated for peripheral arterial disease or peripheral arterial aneurysm requiring bypass treated with GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft

GORE® PROPATEN® Vascular Graft

Intervention Type DEVICE

Patients that have had treatment with GORE® PROPATEN® Vascular Graft

GORE-TEX® Vascular Grafts

Intervention Type DEVICE

Patients that have had treatment with GORE-TEX® Vascular Grafts

AAA Cohort

Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft

GORE-TEX® Vascular Grafts

Intervention Type DEVICE

Patients that have had treatment with GORE-TEX® Vascular Grafts

Dialysis Access Cohort

Patient required the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease using a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft

GORE® PROPATEN® Vascular Graft

Intervention Type DEVICE

Patients that have had treatment with GORE® PROPATEN® Vascular Graft

GORE-TEX® Vascular Grafts

Intervention Type DEVICE

Patients that have had treatment with GORE-TEX® Vascular Grafts

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GORE® PROPATEN® Vascular Graft

Patients that have had treatment with GORE® PROPATEN® Vascular Graft

Intervention Type DEVICE

GORE-TEX® Vascular Grafts

Patients that have had treatment with GORE-TEX® Vascular Grafts

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient is willing and able to provide written informed consent or consent is waived, according to national and local regulations.
2. Patient was at least 18 years of age at the time of implant.

1\. Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft at least 5 years before site initiation. Research device could have been used to replace or bypass either a diseased visceral branch or the aorta itself.

Exclusion Criteria

1. Patient was not available for follow up (on-site or remotely) at the clinical site, with the exception of death (e.g., patient lost to follow-up immediately after treatment, patients who live far away from the clinical site and are not available to share follow-up data performed locally).
2. At the time of treatment, patient had known coagulation disorders, including hypercoagulability, that were not amenable to treatment.
3. Patient was pregnant at the time of treatment.
4. Patient had known or suspected systemic infection or infection at the site of graft implantation at the time of implant.
5. Patient had a separate major interventional or surgical vascular procedure within 30 days prior to treatment. CVC catheter placement would be permitted.
6. Patient is already enrolled in this registry under a different cohort.

At the time of treatment, the patient must not have met any of the following criteria:

1. Patient had percutaneous transluminal angioplasty (PTA) or stenting of the target artery at the anticipated site of the proximal or distal anastomosis within 30 days prior to the index procedure. Use of PTA or stenting during the index procedure is permitted.
2. Patient had a stroke or myocardial infarction (MI) within 6 weeks prior to the index procedure.
3. Patient has previous instance of Heparin-induced Thrombocytopenia type 2 or has known hypersensitivity to heparin.
4. Patient required composite bypass for index procedure (graft + significant length of autologous vessel). Autologous "cuffs" or patches are allowed.

At the time of treatment, the patient must not have met any of the following criteria:

1\. Patient required emergency surgery due to aneurysm rupture.

At the time of treatment, the patient must not have met any of the following criteria:

1. The patient had a previous documented and unsuccessfully treated ipsilateral central venous stenosis via imaging technique.
2. The patient was taking maintenance immunosuppressant medication at the time of implant such as rapamycin, mycophenolate or mycophenolic acid, prednisone (\> 10 mg), cyclosporine, tacrolimus, or cyclophosphamide.
3. The patient has had a previous instance of Heparin-Induced Thrombocytopenia type 2 (HIT-2) or has known sensitivity to heparin.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No